Skip to content
Open access

Large increase in mortality and hospital admissions among young children and the aged due to Influenza and Respiratory Syncytial Virus in Brazil in 2025

Aug 2026 · medRxiv · 0 citations
Medicine

TL;DR

While deaths and hospital admissions caused by SARS-CoV-2 declined rapidly since 2023, mortality rates of other respiratory viruses, mainly influenza and RSV, increased significantly among children <5 years and the aged in 2025/2.

Abstract

Background: Mortality and hospital admissions due to Severe Acute Respiratory Infection (SARI) peaked between January and August 2025 in Brazil. Methods: The Brazilian Ministry of Health data on hospital admissions and deaths caused by SARI were compiled by age group (<5, 5-14, 15-49, 50-64, 65+ years) and quarter between January 2023 and June 2025. SARI causes were aggregated into SARS-Cov-2, Influenza, Respiratory Syncytial Virus (RSV), and other viruses (parainfluenza, adenovirus, rhinovirus, bocavirus, metapneumovirus). Multinomial regression was used to impute likely causes of death when these were not laboratory confirmed. Results: In the second quarter of 2025 (2025/2), RSV mortality rate among children <5 years reached 60 per 100,000, which is a 43% increase compared with 2024/2. Mortality rate for the joint impact of parainfluenza, adenovirus, rhinovirus, bocavirus, and metapneumovirus in the same age group doubled from 20 to 40 on the same scale in 2025/2 compared to 2024/2. Over the same period, influenza mortality tripled among the aged, whereas mortality due to other respiratory viruses increased less dramatically, except for SARS-CoV-2, which decreased among the aged from 150 to 25 per 100,000 between 2023/1 and 2025/2. Other age groups remained relatively stable over the period. The variation in hospital admissions largely followed that of mortality. Conclusions: While deaths and hospital admissions caused by SARS-CoV-2 declined rapidly since 2023, mortality rates of other respiratory viruses, mainly influenza and RSV, increased significantly among children <5 years and the aged in 2025/2. Public health policies that facilitate vaccine uptake against these infections should be given high priority.

Read PDF

Similar papers

Open access Oct 2026

Mortality and vaccine-preventable deaths from severe acute respiratory infections in Brazil in 2026

Background: A large increase in mortality from severe acute respiratory infections (SARI) in Brazil in 2025 was mainly driven by influenza A and respiratory syncytial virus (RSV) among children and the aged, but 2026 data remain largely unpublished. Methods: Secondary data on SARI by age group (<2, 2-4, 5-14, 15-49, 50...

E. Kupek · 0 citations
Open access Sep 2026

Trends and estimated costs of hospitalizations potentially associated with respiratory syncytial virus among children in Brazil, 2014-2025

The association between prolonged hospitalization and higher expenditures underscores the need for targeted, region-specific preventive strategies and timely clinical interventions, to reduce the growing economic burden on the system.

Felipe Cotrim de Carvalho, W. A. F. de Almeida, Daiana Araújo da Silva et al. · 0 citations
Open access Sep 2026

Burden of respiratory syncytial virus (RSV) hospitalizations among adults aged 60 years or more in Brazil: A retrospective surveillance database analysis (2013–2024)

Background Globally, respiratory syncytial virus (RSV) is a leading cause of severe respiratory illness in adults aged ≥60 years. Risk increases with advancing age and comorbidities, particularly cardiopulmonary disease and diabetes. RSV disease burden in adults is often underestimated due to non-specific presentation...

B. D. de Veras, L. Michelin, Julio Croda et al. · 0 citations
Open access Sep 2026

Characteristics and outcomes of adult patients hospitalised with RSV infection, influenza or COVID-19 in Belgium, winter seasons 2023/24 and 2024/25

Patients with RSV infection had a disease course comparable to patients with influenza or COVID-19 and a higher mortality rate, especially with increasing age, highlighting the importance of RSV vaccination in older adults and those with comorbidities, alongside established vaccination strategies for seasonal influenza...

Y. Lafort, Cato Dambre, Y. Dockx et al. · 0 citations
Open access Sep 2026

Protective effect of influenza vaccine in Brazilian patients hospitalised for severe acute respiratory infection, 2023-2025

Two doses of influenza vaccine were moderately effective in decreasing in-hospital mortality and stay among SARI-hospitalised influenza patients, and including 50-59-year-olds in a priority vaccination group may significantly reduce influenza-related adverse outcomes.

E. Kupek · 0 citations
Open access Aug 2026

Trends in Mortality and the Effects of the Coronavirus Disease 2019 Pandemic on Mortality Among Adult Patients With Staphylococcus aureus Bacteremia, 20 US Counties, 2005-2022.

Background Trends in Staphylococcus aureus bacteremia (SAB) mortality in the United States, including the impact of coronavirus disease 2019, have not been well described. Methods Active, laboratory- and population-based surveillance data from 20 counties (7 states) were used to examine annual, 30-day mortality rates...

Carly Adams, Holly M. Biggs, Kelly A. Jackson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.